Non-invasive Prenatal Testing (NIPT) Market – High awareness regarding benefits of non-invasive testing methods is expected to boost the growth of the market
Non-invasive Prenatal Testing (NIPT) Market – High awareness regarding benefits of non-invasive testing methods is expected to boost the growth of the market
Published by Coherent Market Insights
Posted on September 28, 2021
Non-invasive prenatal testing (NIPT) is a DNA test on maternal blood to screen pregnancies for the most common fetal chromosome anomalies such as trisomy 21 that is Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau syndrome. During non-invasive prenatal testing DNA from the mother and fetus is extracted from maternal blood sample and it is recommended for women who have risk factors for having a baby who has a chromosomal condition. Increasing launches and approvals of new non-invasive prenatal tests (NIPT) along with increasing prevalence of chromosomal disorders is expected to propel the market growth during the forecasted period.
Key Players Profiled in the Non-invasive Prenatal Testing (NIPT) MarketReport are as follows: Ariosa Diagnostics, Inc., BGI Diagnosis Co., Ltd., Berry Genomics Corporation, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom, Inc., Natera, Inc., Axia Women’s Health, Eluthia, BillionToOne, Inc., and Quest Diagnostics Incorporated.
The global non-invasive prenatal testing market was valued at US$ 882.9 Mn in 2019 and is forecast to reach a value of US$ 1,936.4 Mn by 2027 at a CAGR of 10.3% between 2020 and 2027.
High prevalence of chromosomal disorders is expected to propel growth of the global non-invasive prenatal testing market over the forecast period. For instance, according to the study, ‘Estimating Nationwide Prevalence of Live Births with Down Syndrome and Their Medical Expenditures in Korea’, published in Journal of Korean Medical Science in August 2019, the prevalence of live births with Down’s syndrome was 5.03 per 10,000 births between 2007 and 2016.
Moreover, high awareness regarding benefits of non-invasive testing methods is also expected to aid in growth of the global non-invasive prenatal testing market. Obstetricians are increasingly recommending patients to undergo non-invasive tests as an alternative to invasive methods and initial diagnostic screening in the first trimester of a pregnancy.
Non-invasive prenatal testing (NIPT) is a DNA test on maternal blood to screen pregnancies for the most common fetal chromosome anomalies such as trisomy 21 that is Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau syndrome. During non-invasive prenatal testing DNA from the mother and fetus is extracted from maternal blood sample and it is recommended for women who have risk factors for having a baby who has a chromosomal condition. Increasing launches and approvals of new non-invasive prenatal tests (NIPT) along with increasing prevalence of chromosomal disorders is expected to propel the market growth during the forecasted period.
Key Players Profiled in the Non-invasive Prenatal Testing (NIPT) MarketReport are as follows: Ariosa Diagnostics, Inc., BGI Diagnosis Co., Ltd., Berry Genomics Corporation, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom, Inc., Natera, Inc., Axia Women’s Health, Eluthia, BillionToOne, Inc., and Quest Diagnostics Incorporated.
The global non-invasive prenatal testing market was valued at US$ 882.9 Mn in 2019 and is forecast to reach a value of US$ 1,936.4 Mn by 2027 at a CAGR of 10.3% between 2020 and 2027.
High prevalence of chromosomal disorders is expected to propel growth of the global non-invasive prenatal testing market over the forecast period. For instance, according to the study, ‘Estimating Nationwide Prevalence of Live Births with Down Syndrome and Their Medical Expenditures in Korea’, published in Journal of Korean Medical Science in August 2019, the prevalence of live births with Down’s syndrome was 5.03 per 10,000 births between 2007 and 2016.
Moreover, high awareness regarding benefits of non-invasive testing methods is also expected to aid in growth of the global non-invasive prenatal testing market. Obstetricians are increasingly recommending patients to undergo non-invasive tests as an alternative to invasive methods and initial diagnostic screening in the first trimester of a pregnancy.
